Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MELINTA THERAPEUTICS, INC. /NEW/MLNT · Entity 154249 | Chief Financial Officer | May 16, 2019 | May 20, 2019 |
| MILESTONE SCIENTIFIC INC.MLSS · Entity 7313 | President | August 01, 2023 | August 10, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MELINTA THERAPEUTICS, INC. /NEW/
Report date May 16, 2019 · Filed May 20, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 150,000 |
Reported balance
After 2019-05-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-16 · Grant · Acquired 150,000 · Balance 150,000 F1: The restricted stock units will vest in equal semi-annual installments over the two year period following May 16, 2019, subject to Mr. Milligan's continued service with the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units will vest in equal semi-annual installments over the two year period following May 16, 2019, subject to Mr. Milligan's continued service with the Issuer through the applicable vesting date.
MILESTONE SCIENTIFIC INC.
Report date August 01, 2023 · Filed August 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, Par Value $0.001SEC Table I · non-derivative | Direct | 124,421 |
Reported balance
After 2023-08-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-08-01 · Grant · Acquired 46,296 · Balance 124,421 F1: 124,421 of these shares are issuable to the reporting person at the termination of employment |
Filing footnotes · ownership attribution and instrument terms
F1: 124,421 of these shares are issuable to the reporting person at the termination of employment
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2023 Filed Aug 10, 2023 23:28 UTC | MILESTONE SCIENTIFIC INC. MLSS · Entity 7313 | GrantCommon Stock, Par Value $0.001 | 46,296 | $1.08 | $49,999.68 |
DisclosureSEC source: 0001437749-23-023148 · rdgdoc.xml · nonDerivative · entry 1 Milligan Peter J · CIK 0001531049 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,421 F1 · balance_after: 124,421 of these shares are issuable to the reporting person at the termination of employment Read SEC document |
| May 16, 2019 Filed May 20, 2019 20:21 UTC | MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249 | GrantRestricted Stock Units · Derivative | 150,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-014223 · doc4.xml · derivative · entry 1 Milligan Peter J · CIK 0001531049 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units will vest in equal semi-annual installments over the two year period following May 16, 2019, subject to Mr. Milligan's continued service with the Issuer through the applicable vesting date. F1 · derivative.expiration_date: The restricted stock units will vest in equal semi-annual installments over the two year period following May 16, 2019, subject to Mr. Milligan's continued service with the Issuer through the applicable vesting date. Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 18:05 UTC | MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249 | GrantStock Option (right to buy) · Derivative | 370,000 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0000899243-18-025192 · doc4.xml · derivative · entry 1 Milligan Peter J · CIK 0001531049 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,000 Underlying: Common Stock · 370,000 shares Expires 2028-09-21 F1 · derivative.exercise_date: One-quarter of the options will vest and become exercisable on September 17, 2019 and the remainder will vest and become exercisable in substantially equal monthly installments during the three year period commencing on September 17, 2019, subject to Mr. Milligan's continued service with the Company through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.